John Paulson Esperion Therapeutics, Inc. Transaction History
Paulson & Co. Inc.
- $1.65 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding ESPR
# of Institutions
217Shares Held
127MCall Options Held
1.61MPut Options Held
1.1M-
Wasatch Advisors Inc Salt Lake City, UT24.5MShares$45.5 Million0.27% of portfolio
-
Black Rock Inc. New York, NY14MShares$26 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21.8 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$18.5 Million0.44% of portfolio
-
Morgan Stanley New York, NY6.31MShares$11.7 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $124M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...